CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO established for the development and operation of CancerLinQ™, recently announced its first Chief Executive Officer (CEO), as well as an additional member of its Board of Governors.

In August, Kevin Fitzpatrick began his new role as CEO of CancerLinQ LLC. Mr. Fitzpatrick was previously the Executive Vice President and Chief Innovation Officer of the American College of Cardiology (ACC).

“Mr. Fitzpatrick has the expertise and experience to make CancerLinQ the learning health system of choice for oncologists,” said ASCO CEO and CancerLinQ LLC Board of Governors Chair Allen S. Lichter, MD, FASCO. “The ACC is a leader in developing and implementing electronic health registries for outpatient care, and he was a driving force in their expansion and utilization. We are thrilled to have Mr. Fitzpatrick bringing this same focus and commitment to CancerLinQ.”

Building upon collaborative efforts

With oversight from the CancerLinQ LLC Board of Governors, the CEO will lead both CancerLinQ and ASCO staff throughout the organization to drive the mission, operations, and financial sustainability of CancerLinQ. Mr. Fitzpatrick will build upon a highly dynamic and collaborative effort within CancerLinQ, ASCO, and SAP to develop a system that is a nimble driver of change in the ever-evolving field of data and analytics.

“I am honored to lead this transformational initiative,” said Mr. Fitzpatrick. “CancerLinQ truly has the potential to change the cancer care landscape, and I look forward to working with the oncology and health information technology (HIT) communities to make that happen.”

Mr. Fitzpatrick jointly led the ACC’s overall financial management and operational and strategic planning. He also served as the Chief Senior Liaison between the ACC and its major corporate, electronic health record, HIT, and institutional partners, and oversees efforts to identify early-stage entrepreneurs tackling some of the biggest challenges facing health care today.

New Board of Governors member

Ronald A. “Ronnie” Andrews, Jr., has also joined CancerLinQ LLC’s Board of Governors. Mr. Andrews has nearly 30 years of experience in the clinical and molecular diagnostics industry, 10 of which were in executive roles at Thermo Fisher Scientific, Life Technologies, General Electric, and Clarient, Inc.

“We are grateful that Mr. Andrews has joined our effort to improve cancer care through big data,” said Dr. Lichter. “He is a forward-thinking ambassador for democratizing information to better manage care and providing physicians in all settings with the most up-to-date information, two fundamental principles of CancerLinQ. His knowledge and ideals will tremendously aid our efforts to contribute to high-quality, personalized cancer care for every patient.”

Each of CancerLinQ LLC’s Board of Governors brings expertise from the technology, business, and informatics sectors, as well as from the field of oncology. Members of the Board of Governors are appointed by the ASCO Board of Directors.

CancerLinQ is a project of CancerLinQ LLC. CancerLinQ is supported through the Conquer Cancer Foundation of ASCO.